552 related articles for article (PubMed ID: 26269187)
1. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
[TBL] [Abstract][Full Text] [Related]
2. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus.
Ramachandran M; Yu D; Dyczynski M; Baskaran S; Zhang L; Lulla A; Lulla V; Saul S; Nelander S; Dimberg A; Merits A; Leja-Jarblad J; Essand M
Clin Cancer Res; 2017 Mar; 23(6):1519-1530. PubMed ID: 27637889
[No Abstract] [Full Text] [Related]
3. Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting.
Ylösmäki E; Martikainen M; Hinkkanen A; Saksela K
J Virol; 2013 Jan; 87(1):335-44. PubMed ID: 23077310
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
[TBL] [Abstract][Full Text] [Related]
5. Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity.
Sarén T; Ramachandran M; Martikainen M; Yu D
Mol Ther Oncolytics; 2017 Dec; 7():67-75. PubMed ID: 29159280
[TBL] [Abstract][Full Text] [Related]
6. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.
Määttä AM; Mäkinen K; Ketola A; Liimatainen T; Yongabi FN; Vähä-Koskela M; Pirinen R; Rautsi O; Pellinen R; Hinkkanen A; Wahlfors J
Int J Cancer; 2008 Oct; 123(7):1704-11. PubMed ID: 18651570
[TBL] [Abstract][Full Text] [Related]
7. The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons.
Fragkoudis R; Breakwell L; McKimmie C; Boyd A; Barry G; Kohl A; Merits A; Fazakerley JK
J Gen Virol; 2007 Dec; 88(Pt 12):3373-3384. PubMed ID: 18024907
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
[TBL] [Abstract][Full Text] [Related]
9. IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma.
Martikainen M; Ramachandran M; Lugano R; Ma J; Martikainen MM; Dimberg A; Yu D; Merits A; Essand M
Mol Ther Oncolytics; 2021 Jun; 21():37-46. PubMed ID: 33869741
[TBL] [Abstract][Full Text] [Related]
10. Replicase complex genes of Semliki Forest virus confer lethal neurovirulence.
Tuittila MT; Santagati MG; Röyttä M; Määttä JA; Hinkkanen AE
J Virol; 2000 May; 74(10):4579-89. PubMed ID: 10775594
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
14. mRNA expression of proinflammatory cytokines in mouse CNS correlates with replication rate of semliki forest virus but not with the strain of viral proteins.
Tuittila M; Nygårdas P; Hinkkanen A
Viral Immunol; 2004; 17(2):287-97. PubMed ID: 15279706
[TBL] [Abstract][Full Text] [Related]
15. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
[TBL] [Abstract][Full Text] [Related]
17. A single amino acid change in the nuclear localization sequence of the nsP2 protein affects the neurovirulence of Semliki Forest virus.
Fazakerley JK; Boyd A; Mikkola ML; Kääriäinen L
J Virol; 2002 Jan; 76(1):392-6. PubMed ID: 11739703
[TBL] [Abstract][Full Text] [Related]
18. Semliki Forest virus nonstructural protein 2 is involved in suppression of the type I interferon response.
Breakwell L; Dosenovic P; Karlsson Hedestam GB; D'Amato M; Liljeström P; Fazakerley J; McInerney GM
J Virol; 2007 Aug; 81(16):8677-84. PubMed ID: 17553895
[TBL] [Abstract][Full Text] [Related]
19. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW; Brown MC; Sacco MT; Gromeier M
J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
[TBL] [Abstract][Full Text] [Related]
20. Semliki Forest virus vectors with mutations in the nonstructural protein 2 gene permit extended superinfection of neuronal and non-neuronal cells.
Ehrengruber MU; Goldin AL
J Neurovirol; 2007 Aug; 13(4):353-63. PubMed ID: 17849319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
